HCPCS Code NUCALA: A Comprehensive Guide

NUCALA (mepolizumab) is a groundbreaking biologic medication used to treat severe eosinophilic asthma and other eosinophilic-driven conditions. As healthcare providers and billing specialists navigate the complexities of medical coding, understanding the HCPCS code for NUCALA (J2182) is crucial for accurate billing and reimbursement.

This comprehensive guide explores everything you need to know about HCPCS Code NUCALA, including its clinical applications, billing procedures, dosage guidelines, and financial considerations. Whether you’re a healthcare provider, coder, or patient, this article provides in-depth insights to ensure proper utilization and reimbursement of this life-changing medication.

2. Understanding HCPCS Codes

HCPCS (Healthcare Common Procedure Coding System) is a standardized coding system used for billing Medicare, Medicaid, and private insurers. It consists of two levels:

• Level I: CPT (Current Procedural Terminology) codes for medical procedures.

• Level II: Codes for drugs, supplies, and equipment (e.g., J-codes for injectable medications).

NUCALA is assigned HCPCS code J2182, which is essential for proper claims submission.

3. What Is NUCALA (Mepolizumab)?

NUCALA is a monoclonal antibody that targets interleukin-5 (IL-5), a protein responsible for eosinophil production. By inhibiting IL-5, NUCALA reduces eosinophil levels, decreasing inflammation in conditions like:

• Severe eosinophilic asthma

• Chronic rhinosinusitis with nasal polyps (CRSwNP)

• Eosinophilic granulomatosis with polyangiitis (EGPA)

Mechanism of Action

4. Indications for NUCALA

NUCALA is FDA-approved for:

1. Severe Eosinophilic Asthma (Age 6+)

   • Reduces exacerbations by up to 53% (Clinical trials: MENSA, DREAM).

2. EGPA (Age 18+)

   • Helps achieve remission in vasculitis.

3. CRSwNP (Age 18+)

   • Improves nasal obstruction and polyp size.

5. HCPCS Code for NUCALA: J2182

Billing Tips:

✔ Report one unit per 1 mg administered.
✔ Verify payer policies (prior authorization often required).
✔ Use ICD-10 codes (e.g., J45.50 for severe eosinophilic asthma).

6. Billing and Reimbursement Guidelines

• Medicare Coverage: Covered under Part B when administered in a physician’s office.

• Private Insurance: Varies by plan; prior authorization typically needed.

• Medicaid: State-dependent; check local policies.

Reimbursement Challenges

• Documentation Requirements: Proof of eosinophil testing and prior treatment failure.

• Appeals Process: May be necessary if initial claims are denied.

7. Dosage and Administration

• Standard Dose: 100 mg subcutaneous injection every 4 weeks.

• Pediatric Dose: 40 mg for children (6-17 years).

• Storage: Refrigerate at 2°C–8°C; avoid freezing.

8. Clinical Efficacy and Safety

Key Clinical Trials

Common Side Effects:

• Headache, injection-site reactions, back pain.

9. Cost and Insurance Coverage

• Average Cost: $4,000–$6,000 per dose.

• Patient Assistance: GSK offers copay cards and financial aid.

10. Comparison with Other Biologics

11. Patient Assistance Programs

• GSK Patient Access

• Medicare Extra Help

• Nonprofit Grants

12. Future Developments

• Oral formulations in research.

• Expanded indications for COPD.

13. Conclusion

NUCALA (HCPCS J2182) is a vital treatment for eosinophilic conditions, offering significant clinical benefits. Proper coding, billing, and patient support ensure optimal access. Staying informed on updates ensures effective patient care and reimbursement success.

14. FAQs

Q1: What is the HCPCS code for NUCALA?
A: J2182 (1 mg injection).

Q2: How often is NUCALA administered?
A: Every 4 weeks (100 mg for adults, 40 mg for children).

Q3: Does Medicare cover NUCALA?
A: Yes, under Part B when given in a clinical setting.